Aromatase Inhibitors Won't Raise Odds of Most Fatal CVD Events

This article originally appeared here.
Share this content:
Aromatase Inhibitors Won't Raise Odds of Most Fatal CVD Events
Aromatase Inhibitors Won't Raise Odds of Most Fatal CVD Events

FRIDAY, April 22, 2016 (HealthDay News) -- Treatment with aromatase inhibitors doesn't raise the risk of the most fatal cardiovascular disease events among breast cancer survivors, according to research published online April 21 in JAMA Oncology.

The new study included 13,273 postmenopausal women. The women were diagnosed between 1991 and 2010 with either progesterone or estrogen receptor-positive breast cancer. The women's health was followed through 2011. In this study, 28.6 percent of the women took aromatase inhibitors, 31.7 percent took tamoxifen, 20.2 percent took both drugs, and 19.4 percent didn't take either drug.

The researchers found that women who took aromatase inhibitors didn't have a higher risk for cardiac ischemia and stroke than those who took tamoxifen. But, women who took only aromatase inhibitors or used them after tamoxifen treatment had up to a 29 percent higher risk of other cardiovascular disease (dysrhythmia, valvular dysfunction, and pericarditis) than those who took only tamoxifen.

"Our study is a comprehensive assessment of the impact aromatase inhibitors have on cardiovascular risk and provides reassurance that the hormone therapy to reduce breast cancer recurrence does not increase risk of the most fatal cardiovascular events," study author Reina Haque, M.D., a research scientist at Kaiser Permanente's Southern California Department of Research and Evaluation, said in a Kaiser news release.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »